Cargando…

Immunotherapeutic potential of blinatumomab-secreting γ9δ2 T Cells

Previous studies have explored the use of engineered blinatumomab-secreting autologous αβ T cells for CD19-targeted cancer therapy. To create a more flexible allogeneic delivery system, we utilized γ9δ2 T cells rather than αβ T cells in a similar application. First, we showed that γ9δ2 T cells could...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Shang-Ju, Lin, Chien-Ting, Liao, Cheng Hao, Lin, Chun-Ming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Neoplasia Press 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10024132/ https://www.ncbi.nlm.nih.gov/pubmed/36917873 http://dx.doi.org/10.1016/j.tranon.2023.101650

Ejemplares similares

The potential of adoptive transfer of γ9δ2 T cells to enhance blinatumomab’s antitumor activity against B-cell malignancy
por: Chen, Yun-Hsiang, et al.
Publicado: (2021)

Emerging Challenges of Preclinical Models of Anti-tumor Immunotherapeutic Strategies Utilizing Vγ9Vδ2 T Cells
por: Joalland, Noémie, et al.
Publicado: (2020)

Blinatumomab-associated vasculitis
por: Liau, MeiQi May, et al.
Publicado: (2017)

Human Vδ2 T Cells and Their Versatility for Immunotherapeutic Approaches
por: Sanz, Marta, et al.
Publicado: (2022)

Nanoformulated Zoledronic Acid Boosts the Vδ2 T Cell Immunotherapeutic Potential in Colorectal Cancer
por: Di Mascolo, Daniele, et al.
Publicado: (2019)

Blinatumomab in Relapsed/Refractory Burkitt Lymphoma
por: Bohler, Jeanne, et al.
Publicado: (2022)

Molecular and clinical characterization of PARP9 in gliomas: A potential immunotherapeutic target
por: Xu, Hao, et al.
Publicado: (2020)

Potential for bispecific T-cell engagers: role of blinatumomab in acute lymphoblastic leukemia
por: Le Jeune, Caroline, et al.
Publicado: (2016)

Advancements in Therapy for Acute Lymphoblastic Leukemia: Blinatumomab
por: Hladnik,1, Lindsay, et al.
Publicado: (2016)

Blinatumomab in Ph+ B-ALL: present and perspectives
por: Papayannidis, Cristina, et al.
Publicado: (2017)

Recent advances on blinatumomab for acute lymphoblastic leukemia
por: Zhao, Juanjuan, et al.
Publicado: (2019)

Cytokine Release Syndrome Following Blinatumomab Therapy
por: Ojemolon, Pius E, et al.
Publicado: (2022)

Profile of blinatumomab and its potential in the treatment of relapsed/refractory acute lymphoblastic leukemia
por: Ribera, Josep-Maria, et al.
Publicado: (2015)

Allogenic Vγ9Vδ2 T cell as new potential immunotherapy drug for solid tumor: a case study for cholangiocarcinoma
por: Alnaggar, Mohammed, et al.
Publicado: (2019)

Blinatumomab-induced T cell activation at single cell transcriptome resolution
por: Huo, Yi, et al.
Publicado: (2021)

REGγ Contributes to Regulation of Hemoglobin and Hemoglobin δ Subunit
por: Zuo, Qiuhong, et al.
Publicado: (2017)

TGF-β1 potentiates Vγ9Vδ2 T cell adoptive immunotherapy of cancer
por: Beatson, Richard E., et al.
Publicado: (2021)

Sensing of Pyrophosphate Metabolites by Vγ9Vδ2 T Cells
por: Gu, Siyi, et al.
Publicado: (2015)

Role of Vγ9vδ2 T lymphocytes in infectious diseases
por: Gay, Laetitia, et al.
Publicado: (2022)

Immunotherapeutic Potential of T Memory Stem Cells
por: Li, Yujie, et al.
Publicado: (2021)

γ9δ2 T-Cell Expansion and Phenotypic Profile Are Reflected in the CDR3δ Repertoire of Healthy Adults
por: Vyborova, Anna, et al.
Publicado: (2022)

Phenotype and functional changes of Vγ9/Vδ2 T lymphocytes in Behçet's disease and the effect of infliximab on Vγ9/Vδ2 T cell expansion, activation and cytotoxicity
por: Accardo-Palumbo, Antonina, et al.
Publicado: (2010)

Lifespan of γ/δ T Cells
por: Tough, David F., et al.
Publicado: (1998)

New γ-Halo-δ-lactones and δ-Hydroxy-γ-lactones with Strong Cytotoxic Activity
por: Kamizela, Angelika, et al.
Publicado: (2019)

Pharmacokinetic and Pharmacodynamic Relationship of Blinatumomab in Patients with Non-Hodgkin Lymphoma
por: Hijazi, Youssef, et al.
Publicado: (2018)

Immunotherapeutic Potential of Extracellular Vesicles
por: Zhang, Bin, et al.
Publicado: (2014)

Potential Immunotherapeutics for Immunosuppression in Sepsis
por: Shin, Jinwook, et al.
Publicado: (2017)

Biomarkers associated with blinatumomab outcomes in acute lymphoblastic leukemia
por: Wei, Andrew H., et al.
Publicado: (2021)

Relapse and Resistance to CAR-T Cells and Blinatumomab in Hematologic Malignancies
por: Jacoby, Elad
Publicado: (2019)

Linking Innate and Adaptive Immunity: Human Vγ9Vδ2 T Cells Enhance CD40 Expression and HMGB-1 Secretion
por: Kalyan, Shirin, et al.
Publicado: (2009)

The human Vδ2(+) T-cell compartment comprises distinct innate-like Vγ9(+) and adaptive Vγ9(-) subsets
por: Davey, Martin S., et al.
Publicado: (2018)

Improving the Efficiency of Vγ9Vδ2 T-Cell Immunotherapy in Cancer
por: Hoeres, Timm, et al.
Publicado: (2018)

Development and Selection of the Human Vγ9Vδ2(+) T-Cell Repertoire
por: Willcox, Carrie R., et al.
Publicado: (2018)

The PPARα pathway in Vγ9Vδ2 T cell anergy
por: Poupot, Mary, et al.
Publicado: (2014)

Releasing the restraints of Vγ9Vδ2 T-cells in cancer immunotherapy
por: Ridgley, Laura A., et al.
Publicado: (2023)

Preferential Infiltration of Unique Vγ9Jγ2-Vδ2 T Cells Into Glioblastoma Multiforme
por: Lee, Mijeong, et al.
Publicado: (2019)

Chitosan Nanoparticles Strengthen Vγ9Vδ2 T-Cell Cytotoxicity Through Upregulation Of Killing Molecules And Cytoskeleton Polarization
por: Lin, Li, et al.
Publicado: (2019)

Single-cell discovery of the scene and potential immunotherapeutic target in hypopharyngeal tumor environment
por: Lin, Chen, et al.
Publicado: (2022)

Infectious Risks and Complications in Adult Leukemic Patients Receiving Blinatumomab
por: So, Wonhee, et al.
Publicado: (2018)

Population Pharmacokinetics of Blinatumomab in Pediatric and Adult Patients with Hematological Malignancies
por: Clements, John David, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_8qb04siec7qdroj0rgi2r8d4gv